Institution:
Albert Einstein College of MedicineResearchers:
Vern L. Schramm, PhD, professor of biochemistry and Ruth Merns Chair in Biochemistry at Albert Einstein College of Medicine
Impact:
Dr. Schramm and his collaborators have developed synthetic compounds based on transition-state inhibitors, which prevent enzymatic reactions. They have developed drugs to treat leukemia and gout, which have moved into clinical trials, and to develop antibiotics that don’t trigger resistance. This knowledge also permits drug design for other disorders.
Timeline:
2009 to present